Evidence map›Paper›PMID 26960396›Full record

ArticleClinical cancer research : an official journal of the American Association for Cancer Research2016

The Genomic Landscape of Male Breast Cancers.

Salvatore Piscuoglio, Charlotte K Y Ng, Melissa P Murray, Elena Guerini-Rocco, Luciano G Martelotto, Felipe C Geyer, Francois-Clement Bidard, Samuel Berman, Nicola Fusco, Rita A Sakr and 12 more

Open access · bronzeAbstract read
In one paragraph

Article in Clinical cancer research : an official journal of the American Association for Cancer Research, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 82 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
82citing papers in PubMed, 1 pooled it
19.8field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

82 citing papers in PubMed, 1 synthesis or guideline pooled it, 148 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Review
  4. Article
  5. Review
  6. Article
  7. Article
  8. Review
  9. Article
  10. Survival Values of Iraqi Male Breast Cancer.Asian Pacific journal of cancer prevention : APJCP · 2025
    Article
  11. Article
  12. Article
  13. Article
  14. Review
  15. Article
  16. Article
  17. Exploring the One Health Paradigm in Male Breast Cancer.Journal of mammary gland biology and neoplasia · 2024
    Review
  18. Review
  19. Article
  20. Article

22 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

22 authors at 2 institutions in 4 countries.

Salvatore PiscuoglioDepartment of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York.
Charlotte K Y NgDepartment of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York.
Melissa P MurrayDepartment of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York.
Elena Guerini-RoccoDepartment of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York. Department of Pathology, European Institute of Oncology, Milan, Italy.
Luciano G MartelottoDepartment of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York.
Felipe C GeyerDepartment of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York. Department of Pathology, Hospital Israelita Albert Einstein, Instituto Israelita de Ensino e Pesquisa, São Paulo, Brazil.
Francois-Clement BidardDepartment of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York. Department of Medical Oncology, Institut Curie, Paris, France.
Samuel BermanDepartment of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York.
Nicola FuscoDepartment of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York. Division of Pathology, Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico, Milan, Italy.
Rita A SakrDepartment of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York.
Carey A EberleDepartment of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York.
Leticia De Mattos-ArrudaDepartment of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York.
Gabriel S MacedoDepartment of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York.
Muzaffar AkramDepartment of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York.
Timour BaslanCold Spring Harbor Laboratory, Cold Spring Harbor, New York. Department of Molecular and Cellular Biology, Stony Brook University, Stony Brook, New York. Department of Cancer Biology and Genetics, Memorial Sloan Kettering Cancer Center, New York, New York.
James B HicksCold Spring Harbor Laboratory, Cold Spring Harbor, New York.
Tari A KingDepartment of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York.
Edi BrogiDepartment of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York.
Larry NortonDepartment of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.
Britta WeigeltDepartment of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York.
Clifford A HudisDepartment of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.
Jorge S Reis-FilhoDepartment of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York. reisfilj@mskcc.org.
Memorial Sloan Kettering Cancer Center · USCold Spring Harbor Laboratory · US

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Nicholas D Socci · 1985 to 2026
$347.4M
NCI NIH HHS P30 CA008748
6 · The paper itself

Abstract

purposeMale breast cancer is rare, and its genomic landscape has yet to be fully characterized. Lacking studies in men, treatment of males with breast cancer is extrapolated from results in females with breast cancer. We sought to define whether male breast cancers harbor somatic genetic alterations in genes frequently altered in female breast cancers. EXPERIMENTAL

designAll male breast cancers were estrogen receptor-positive, and all but two were HER2-negative. Fifty-nine male breast cancers were subtyped by immunohistochemistry, and tumor-normal pairs were microdissected and subjected to massively parallel sequencing targeting all exons of 241 genes frequently mutated in female breast cancers or DNA-repair related. The repertoires of somatic mutations and copy number alterations of male breast cancers were compared with that of subtype-matched female breast cancers.

resultsTwenty-nine percent and 71% of male breast cancers were immunohistochemically classified as luminal A-like or luminal B-like, respectively. Male breast cancers displayed a heterogeneous repertoire of somatic genetic alterations that to some extent recapitulated that of estrogen receptor (ER)-positive/HER2-negative female breast cancers, including recurrent mutations affecting PIK3CA (20%) and GATA3 (15%). ER-positive/HER2-negative male breast cancers, however, less frequently harbored 16q losses, and PIK3CA and TP53 mutations than ER-positive/HER2-negative female breast cancers. In addition, male breast cancers were found to be significantly enriched for mutations affecting DNA repair-related genes.

conclusionsMale breast cancers less frequently harbor somatic genetic alterations typical of ER-positive/HER2-negative female breast cancers, such as PIK3CA and TP53 mutations and losses of 16q, suggesting that at least a subset of male breast cancers are driven by a distinct repertoire of somatic changes. Given the genomic differences, caution may be needed in the application of biologic and therapeutic findings from studies of female breast cancers to male breast cancers. Clin Cancer Res; 22(16); 4045-56. ©2016 AACR.

Indexed as

Biomarkers, TumorGenetic Predisposition to DiseaseGenomicsAdultAgedAged, 80 and overBreast NeoplasmsBreast Neoplasms, MaleComparative Genomic HybridizationDNA Copy Number VariationsFemaleHigh-Throughput Nucleotide SequencingHumansImmunohistochemistryMaleMiddle AgedBiomarkers, Tumor

Identifiers

PMID26960396
PMCPMC4987160
OpenAlexW2421692008

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.